Intarcia Therapeutics

• NCT03060980

  Phase 3, Terminated, 245 people, 23 Feb 2017

• NCT02650479

  Phase 1, Completed, 82 people, 8 Jan 2016

• NCT02641899

  Phase 1, Completed, 33 people, 30 Dec 2015

• NCT02638805

  Phase 3, Completed, 136 people, 23 Dec 2015

• NCT01455922

  Phase 3, Withdrawn, 0 people, 20 Oct 2011

• NCT01455883

  Phase 3, Withdrawn, 0 people, 20 Oct 2011

• NCT01455909

  Phase 3, Withdrawn, 0 people, 20 Oct 2011

• NCT01455870

  Phase 3, Completed, 535 people, 20 Oct 2011

• NCT00943917

  Phase 2, Completed, 155 people, 22 Jul 2009

• NCT00267553

  Phase 3, Terminated, 200 people, 21 Dec 2005

• NCT00097344

  Phase 3, Terminated, 842 people, 23 Nov 2004

• NCT00044291

  Phase 3, Completed, 865 people, 27 Aug 2002

• Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials

  Consulting or advice, 20 Aug 2021

• Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1-5 trials

  Consulting or advice, Board or leadership role, 7 Jun 2018

Sources: pubmed.ncbi.nlm.nih.gov